Biomarkers and Adjuvant Treatment Planning Strategies for Patients with a Node-Negative, Estrogen Receptor-Positive Breast Cancer
David M. Hyams, MD, FACS and Ruth Oratz, MD, FACP

Molecularly Targeted Therapies for Breast Cancer
Timothy J. Hobday, MD; Edith A. Perez, MD

Monoclonal Antibody Therapy for Breast Cancer
Edith A. Perez, MD - Mayo Clinic Cancer Center, Jacksonville, Florida

Medical Genomics: Implications for Clinical Oncology
Charles H. Weaver, MD, and Dayna Deuter

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole (3/10/2010)
Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Avastin® Not Contraindicated in Patients with CNS Metastases (3/8/2010)
Researchers from France have reported that patients with central nervous system (CNS) metastases have similar rates of whether or not they receive Avastin® (bevacizumab). The details of this study appeared in the January 2010 issue of Clinical Cancer Research.

Bisphosphonates for Osteoporosis Treatment May Decrease Risk of Breast Cancer (3/4/2010)
Researchers from the University of Wisconsin have reported that the use of bisphosphonates for osteoporosis treatment may reduce the risk of developing breast cancer. The details of this study were published in the March 1, 2010 issue of the British Journal of Cancer.

Oncotype DX® Recurrence Scores Similar in United States and Asia-Pacific (3/3/2010)
Researchers have reported that the results of the Oncotype DX® breast cancer test are similar among patients in the United States and Asia-Pacific, suggesting that the test may help guide breast cancer treatment decisions in both regions. These results were presented at the 6^th Annual Conference of the Organisation for Oncology and Translational Research (OOTR) in Japan in February 2010.

Regular Aspirin Use Decreases Distant Recurrences and Decreases Breast Cancer Deaths in Women with Early-stage Breast Cancer (2/26/2010)
Researchers affiliated with the Nurses’ Health Study have reported that women with early-stage breast cancer living at least one year after diagnosis have a decreased risk of distant relapse and lower mortality if they are regular users of aspirin.